Protagonist Therapeutics Inc
NASDAQ:PTGX

Watchlist Manager
Protagonist Therapeutics Inc Logo
Protagonist Therapeutics Inc
NASDAQ:PTGX
Watchlist
Price: 53.34 USD -1.08%
Market Cap: 3.3B USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

PTGX Price Targets Summary
Protagonist Therapeutics Inc

Wall Street analysts forecast PTGX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PTGX is 70.38 USD with a low forecast of 41.41 USD and a high forecast of 86.1 USD.

PTGX Lowest Forecast
Wall Street Target
41.41 USD
22% Downside
PTGX Average Forecast
Wall Street Target
70.38 USD
32% Upside
PTGX Highest Forecast
Wall Street Target
86.1 USD
61% Upside
Lowest
Price Target
41.41 USD
22% Downside
Average
Price Target
70.38 USD
32% Upside
Highest
Price Target
86.1 USD
61% Upside
Protagonist Therapeutics Inc Competitors:
Price Targets
B
251120
Bio-FD&C Co Ltd
4% Downside
J
600201
Jinyu Bio-Technology Co Ltd
3% Upside
TRDA
Entrada Therapeutics Inc
194% Upside
SPRO
Spero Therapeutics Inc
69% Upside
B
251120
Bio-FD&C Co Ltd
4% Downside
J
600201
Jinyu Bio-Technology Co Ltd
3% Upside
TRDA
Entrada Therapeutics Inc
194% Upside
SPRO
Spero Therapeutics Inc
69% Upside
VCYT
Veracyte Inc
62% Upside
Y
002675
Yantai Dongcheng Biochemicals Co Ltd
8% Upside
KALV
Kalvista Pharmaceuticals Inc
129% Upside
S
6955
Shandong Boan Biotechnology Co Ltd
17% Downside

Revenue
Forecast

Revenue Estimate
Protagonist Therapeutics Inc

The compound annual growth rate of Protagonist Therapeutics Inc's revenue for the next 3 years is -21%.

N/A
Past Growth
-21%
Estimated Growth
Estimates Accuracy
11%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Protagonist Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Protagonist Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-47%
Average Miss
What are analyst estimates?

See Also

Summary
PTGX intrinsic value, competitors valuation, and company profile.
DCF Valuation
PTGX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
PTGX stock valuation using valuation multiples.
Wall Street Estimates
PTGX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
PTGX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is PTGX's stock price target?
Price Target
70.38 USD

According to Wall Street analysts, the average 1-year price target for PTGX is 70.38 USD with a low forecast of 41.41 USD and a high forecast of 86.1 USD.

What is Protagonist Therapeutics Inc's Revenue forecast?
Projected CAGR
-21%

The compound annual growth rate of Protagonist Therapeutics Inc's revenue for the next 3 years is -21%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 263,300+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.